Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigil
| Current Price | ₹440.85 |
|---|---|
| Market Cap | ₹17,550 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services |
| P/E Ratio | 56 |
| Return on Equity | 6.62% |
| 52-Week Range | ₹380.00 – ₹728.60 |
| Beta (1Y) | 0.28 |
| Dividend Yield | 0.28% |
1. Providing Contract Research and Manufacturing Services-100%
Syngene International Ltd. is trading at ₹440.85, with a market capitalisation of ₹17,550 Cr.
Syngene International Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services).
Syngene International Ltd. has a P/E of 56 and a return on equity of 6.62%.